United Therapeutics
UTHR
427 hedge funds and large institutions have $7.82B invested in United Therapeutics in 2022 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 145 increasing their positions, 157 reducing their positions, and 44 closing their positions.
41% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 44
32% more call options, than puts
Call options by funds: $68.7M | Put options by funds: $52.1M
3% more funds holding
Funds holding: 416 → 427 (+11)
1.77% more ownership
Funds ownership: 95.98% → 97.75% (+1.8%)
8% less repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 157
15% less capital invested
Capital invested by funds: $9.19B → $7.82B (-$1.37B)
18% less funds holding in top 10
Funds holding in top 10: 17 → 14 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$135M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$104M |
| 3 |
Morgan Stanley
New York
|
+$44.3M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$37.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$53.3M |
| 2 |
Bank of New York Mellon
New York
|
-$34.6M |
| 3 |
Two Sigma Advisers
New York
|
-$31M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$29M |
| 5 |
Renaissance Technologies
New York
|
-$29M |
UTHR Hedge Fund Activity: Q1 2022 in Review
427 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2022, worth a combined $7.82B — down 15% from $9.19B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new UTHR positions and 44 closed out — a net gain of 18 holders — while 145 added to existing stakes and 157 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $135M. The largest seller was Robeco Institutional Asset Management, cutting an estimated $53.3M.
- 427 institutional investors held United Therapeutics (UTHR) as of Q1 2022, up from 416 in Q4 2021.
- Funds reported $7.82B of United Therapeutics stock for Q1 2022, down 15% quarter-over-quarter.
- 62 funds opened new United Therapeutics positions in Q1 2022 and 44 closed out, a net change of +18 holders.
- The largest United Therapeutics buyer in Q1 2022 was Wellington Management Group, an estimated $135M added.
- The largest United Therapeutics seller in Q1 2022 was Robeco Institutional Asset Management, an estimated $53.3M sold.
Based on aggregated 13F filings for Q1 2022.